Quest Diagnostics is making another acquisition. The provider of diagnostic tests and services said it will pay $570 million to private equity partner Welsh, Carson, Anderson and Stowe for Solstas Lab Partners Group.
Intuitive Surgical, beset by quality problems relating to its da Vinci surgical robots, will snatch up medical shape-sensing technology from Virginia's Luna Innovations in a deal worth up to $30 million.
BioMarin is taking a flyer on HDAC inhibitors, taking up Repligen's portfolio in exchange for as much as $162 million and adding candidates in Friedreich's ataxia and other neurological disorders.
The NuPathe love triangle resolved itself quickly. The patch-focused drugmaker decided to accept Teva Pharmaceutical Industries' ($TEVA) higher offer, sending its previous suitor, Endo Health...
Ohio medical device researcher NAMSA is stretching out its European presence with the acquisition of Medvance, snapping up the U.K.-headquartered CRO with hopes of growing its share of the med tech market.
Another year, another merger for BioClinica as the once-public CRO prepares to combine its operations with CCBR-Synarc, a specialized clinical services outfit.
When Shire picked up regenerative medicine operation Dermagraft a few years ago, it quickly turned into a money-losing dog. So Shire has decided to unload Dermagraft, even if it has to take a loss on the sale.
French diagnostics giant bioMérieux finalized its acquisition of U.S.-based BioFire Diagnostics on Thursday. Under the agreement, bioMérieux will pay $450 million and will also assume BioFire's net financial debt, which is estimated at $35 million.
Shire's once-promising foray into regenerative medicine has largely been a bust, and now the Irish company is handing its costly Dermagraft program to Organogenesis in exchange for little but milestone payments.
The merger expands the range of medical imaging services BioClinica can offer while also moving it into new areas, notably clinical trial services and patient recruitment.